Keywords
SARS-CoV-2, 2019-nCoV, 2019 novel coronavirus, severe acute respiratory syndrome coronavirus 2, Covid-19
This article is included in the Emerging Diseases and Outbreaks gateway.
This article is included in the Coronavirus (COVID-19) collection.
SARS-CoV-2, 2019-nCoV, 2019 novel coronavirus, severe acute respiratory syndrome coronavirus 2, Covid-19
The pandemic of coronavirus disease 2019 (COVID-19) caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) presents an unprecedented challenge to rapidly develop new diagnostic, preventive and therapeutic strategies1. Currently, thousands of new COVID-19 patients present for care every day, and many are quickly enrolled in clinical studies. We aimed to investigate the characteristics of the COVID-19 studies registered in ClinicalTrials.gov2, and report the extent to which they have incorporated features that are desirable for generating high-quality evidence.
We investigated the ClinicalTrials.gov website on April 28, 2020, using the search term: SARS-CoV-2 OR 2019-nCoV OR 2019 novel coronavirus OR severe acute respiratory syndrome coronavirus 2 OR Covid-19. No restrictions were applied. No screening of trials was performed; all results were included regardless of their content.
Stata 15.0 (Stata Corp., College Station, TX, USA) was used for the analysis of study characteristics.
A total of 945 studies on COVID-19 have been registered in ClinicalTrials.gov up to April 29, 2020; 586 studies are interventional (62.0%), and 435 of them (74.2%) are randomized. Among interventional studies, the most frequent allocation scheme is the parallel group assignment (437; 74.6%), followed by single group (111; 18.9%], sequential (18; 3.1%), factorial (9; 1.5%), and cross-over assignment (11; 1.9%). The majority of the clinical trials are open-label (no masking, 338 [57.7%]); however, 57 (9.7%) trials are double-blinded, 41 (7.0%) triple-blinded, 90 (15.4%) quadruple-blinded, and 60 (10.2%) single-blinded. Among observational studies, cohort (222; 64.3%) is the most common study design (Table 1).
Most studies target adult or elderly participants, while 178 (18.8%) enroll children, with only five (0.5%) recruiting exclusively children. Median expected study size is 200 (interquartile range, 66–504), although sample sizes vary from ≤100 (344; 37.0%) to >1,000 individuals (148; 15.9%). Overall, only 27 of 945 studies (2.9%) have completed recruitment, 453 (47.9%) are actively recruiting subjects, while a large number of studies (414; 43.8%) are not yet actively recruiting participants. Most of the studies are conducted in Europe (n=327), North America (n=217, of which 186 in the US), East Asia (n=102), Africa (n=27), and in South America (n=26). No study has reported results yet.
Among the interventional studies, the most common primary purpose is the research on treatment (441; 75.3%), followed by prevention (79; 13.5%), supportive care studies (22; 3.8%), and diagnostic investigations (17; 2.9%). Regarding the drugs under scrutiny, hydroxychloroquine (110; 28.6%), azithromycin (38; 9.9%), lopinavir/ritonavir (24; 6.2%), interferon-α and -β (24; 6.2%), glucocorticoids (22; 5.7%), chloroquine (14; 3.6%), favipiravir (10; 2.6%), remdesivir (8; 2.1%), tocilizumab (21; 5.5%), anti-SARS-CoV-2 immunoglobulins (15; 3.9%) and sarilumab (9; 2.3%) account for the majority of interventional studies. Additional details are featured in Table 2.
Our survey presents the current COVID-19 clinical research landscape. Several hundreds of clinical studies have been initiated all over the globe, and the number is growing. Most interventional studies incorporate randomisation, which is considered the hallmark of high-quality clinical trials3, while more than 40% are blinded.
Studies are being conducted especially in the most affected areas: Europe and US. The number of COVID-19 cases in low to middle-income countries is still relatively low, also reflecting scarce testing, but is expected to rise in the next period. These countries will need more research on organizational measures, and trials on interventions that are affordable and applicable to those settings4.
Most studies focus on adults and elderlies, while only few target children, possibly reflecting the observed burden of the disease. Additional effort is needed to ensure that minors are included in COVID-19 clinical research, so that therapeutic decisions are based upon high-quality evidence.
No drug with proven clinical efficacy currently exists for SARS-CoV-2 infection. Despite the absence of solid evidence, several treatments are being currently used in clinical practice in several countries, with sometimes disastrous consequences5. Too many of the ongoing interventional studies have a small expected sample size, and may not generate credible evidence at completion4. This might lead to a delayed recognition of effective therapies that are urgently needed, and a waste of time and resources. In the COVID-19 pandemic era, it is crucial that the adoption of new diagnostic, preventive and therapeutic strategies is based upon evidence coming from well-designed, adequately powered and carefully conducted clinical trials.
The Clinical Trials website can be accessed here: https://clinicaltrials.gov/
Views | Downloads | |
---|---|---|
F1000Research | - | - |
PubMed Central
Data from PMC are received and updated monthly.
|
- | - |
Is the work clearly and accurately presented and does it cite the current literature?
Yes
Is the study design appropriate and is the work technically sound?
Yes
Are sufficient details of methods and analysis provided to allow replication by others?
Partly
If applicable, is the statistical analysis and its interpretation appropriate?
Not applicable
Are all the source data underlying the results available to ensure full reproducibility?
Yes
Are the conclusions drawn adequately supported by the results?
Yes
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: Molecular Epidemiology
Is the work clearly and accurately presented and does it cite the current literature?
Yes
Is the study design appropriate and is the work technically sound?
Yes
Are sufficient details of methods and analysis provided to allow replication by others?
Yes
If applicable, is the statistical analysis and its interpretation appropriate?
Not applicable
Are all the source data underlying the results available to ensure full reproducibility?
Yes
Are the conclusions drawn adequately supported by the results?
Yes
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: Epidemiology, Statistics, Research Methods, Public Health
Alongside their report, reviewers assign a status to the article:
Invited Reviewers | ||
---|---|---|
1 | 2 | |
Version 1 18 May 20 |
read | read |
Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list:
Sign up for content alerts and receive a weekly or monthly email with all newly published articles
Already registered? Sign in
The email address should be the one you originally registered with F1000.
You registered with F1000 via Google, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Google account password, please click here.
You registered with F1000 via Facebook, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Facebook account password, please click here.
If your email address is registered with us, we will email you instructions to reset your password.
If you think you should have received this email but it has not arrived, please check your spam filters and/or contact for further assistance.
Comments on this article Comments (0)